DNA cleavage assay for the identification of topoisomerase I inhibitors

Nature Protocols

Volumn 3, Issue 11, 2008, Pages 1736-1750

  Dexheimer, Thomas S ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; ENZYME INHIBITOR;

ARTICLE; CHEMISTRY; DNA CLEAVAGE; DNA DENATURATION; DNA FLANKING REGION; DNA SEQUENCE; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; ISOTOPE LABELING; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; STRUCTURE ACTIVITY RELATION;

3' FLANKING REGION; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HUMANS; ISOTOPE LABELING; NUCLEIC ACID DENATURATION; SEQUENCE ANALYSIS, DNA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58749110485     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2008.174     Document Type: Article

References (98)

1. Kohlhagen, G., Paull, K., Cushman, M., Nagafufuji, P. and Pommier, Y.: Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison. Mol. Pharmacol. 54, 50-58 (1998).
2. Strumberg, D.: Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J. Med. Chem. 42, 446-457 (1999).
3. Antony, S.: CellularTopoisomerase I Inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol. 67, 523-530 (2005).
4. Ioanoviciu, A.: Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J. Med. Chem. 48, 4803-4814 (2005).
5. Staker, B.L.: Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48, 2336-2345 (2005).
6. Antony, S.: Novelindenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 67, 10397-10405 (2007).
7. Tanizawa, A., Kohn, K.W., Kohlhagen, G., Leteurtre, F. and Pommier, Y.: Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34, 7200-7206 (1995).
8. Pommier, Y.: Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sc'. USA 92, 8861-8865 (1995).
9. Urasaki, Y., Takebayashi, Y. and Pommier, Y.: Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res. 60, 6577-6580 (2000).
10. Gamcsik, M.P.: Dual role ofglutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. Mol. Cancer Ther. 1,11-20 (2001).
11. Takagi, K.: Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol. Cancer Ther. 6, 3229-3238 (2007).
12. Morham, S., Kluckman, K.D., Voulomanos, N. and Smithies, O.: Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol. 16, 6804-6809 (1996).
13. Zhang, C.X., Chen, A.D., Gettel, N.J. and Hsieh, T.S.: Essential functions of DNA topoisomerase I in Drosophila melanogaster. Dev. Biol. 222, 27-40 (2000).
14. Christman, M.F., Dietrich, F.S. and Fink, G.R.: Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerase I and II. Cell 55, 413-425 (1988).
15. Zhang, H.: Human mitochondrialtopoisomerase I. Proc. Natl. Acad. Sd. USA 98, 10608-10613 (2001).
16. Zhang, H., Meng, L.H., Zimonjic, D.B., Popescu, N.C. and Pommier, Y.: Thirteen-exon-motifsignature for vertebrate nuclear and mitochondrialtype IB topoisomerases. Nucleic Acids Res. 32, 2087-2092 (2004).
17. Champoux, J.J.: DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413 (2001).
18. Wang, J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3, 430-440 (2002).
19. Pommier, Y.: Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789-802 (2006).
20. Stewart, L., Redinbo, M.R., Qiu, X., Hol, W.G.J. and Champoux, J.J.: A model for the mechanism of human topoisomerase I. Science 279, 1534-1541 (1998).
21. Lesher, D.T., Pommier, Y., Stewart, L. and Redinbo, M.R.: D8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Natl. Acad. Sd. USA 99, 12102-12107 (2002).
22. Staker, B.L.: The mechanism oftopoisomerase I poisoning byacamptothecin analog. Proc. Natl. Acad. Sci. USA 99, 15387-15392 (2002).
23. Koster, D.A., Croquette, V., Dekker, C., Shuman, S. and Dekker, N.H.: Friction and torque govern the relaxation of DNA supercoils by eukaryotic to poisomerase IB. Nature 434, 671-674 (2005).
24. Leteurtre, F.: Effects of DNA methylation on topoisomerase I and II cleavage activities. J. Biol. Chem. 269, 7893-7900 (1994).
25. Henningfeld, K.A. and Hecht, S.: A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps. Biochemistry 34, 6120-6129 (1995).
26. Yeh, Y.-C., Liu, H.-F., Ellis, C.A. and Lu, A.-L.: Mammalian topoisomerase I has a mismatch nicking activity. J. Biol. Chem. 269, 15498-15504 (1994).
27. Pourquier, P.: Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272, 26441-26447 (1997).
28. Pourquier, P.: Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I.J. Biol. Chem. 272, 7792-7796 (1997).
29. Pourquier, P., Bjornsti, M.A. and Pommier, Y.: Induction oftopoisomerase I cleavage complexes by the vinyl chloride adduct 1, N6-ethenoadenine. J. Biol. Chem. 273, 27245-27249 (1998).
30. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G. and Pommier, Y.: Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sd. USA 96, 7196-7201 (1999).
31. Pourquier, P.: Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin. Cancer Res. 8, 2499-2504 (2002).
32. Pourquier, P. and Pommier, Y.: Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 80, 189-216 (2001).
33. Pourquier, P.: Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res. 61, 53-58 (2001).
34. Dexheimer, T.S., Kozekova, A., Rizzo, C.J., Stone, M.P. and Pommier, Y.: The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA-topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts. Nucleic Acids Res. 36, 4128-4136 (2008).
35. Lanza, A., Tornatelli, S., Rodolfo, C., Scanavini, M.C. and Pedrini, A.M.: Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 271, 6978-6986 (1996).
36. Subramanian, D., Rosenstein, B.S. and Muller, M.T.: Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res. 58, 976-984 (1998).
37. Chrencik, J.E., Burgin, A.B., Pommier, Y., Stewart, L. and Redinbo, M.R.: Structural impact of the leukemia drug Ara-C on the covalent human topoisomerase I DNA complex. J. Biol. Chem. 278, 12461-12466 (2003).
38. Antony, S., Arimondo, P.B., Sun, J.S. and Pommier, Y.: Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures. Nucleic Acids Res. 32, 5163-5173 (2004).
39. Antony, S.: Enhancementofcamptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine. Nucleic Acids Res. 32, 5685-5692 (2004).
40. Pommier, Y.: Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem. 277, 13666-13672 (2002).
41. Pommier, Y.: Benzo[a]pyreneepoxideadductsin DNA arepotentinhibitors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proc. Natl. Acad. Sci. USA 97, 2040-2045 (2000).
42. Pommier, Y.: Position-specific trapping of to poisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine. Proc. Natl. Acad. Sci. USA 97, 10739-10744 (2000).
43. Sordet, O.: Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J. Biol. Chem. 279, 50499-50504 (2004).
44. Sordet, O., Khan, Q.A. and Pommier, Y.: Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle 3, 1095-1097 (2004).
45. Sordet, O.: Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J. Biol. Chem. 279, 33968-33975 (2004).
46. Soe, K., Rockstroh, A., Schache, P. and Grosse, F.: The human topoisomerase I damage response plays a role in apoptosis. DNA Repair (Amst.) 3, 387-393 (2004).
47. Rockstroh, A., Kleinert, A., Kramer, M., Grosse, F. and Soe, K.: Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner. Oncogene 26, 123-131 (2007).
48. Sordet, O., Goldman, A. and Pommier, Y.: Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes. Mol. Cancer Ther. 5, 3139-3144 (2006).
49. Ganguly, A.: Betulinic acid, a catalytic inhibitor oftopoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res. 67, 11848-11858 (2007).
50. Sen, N.: Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ. 14, 358-367 (2007).
51. Sordet, O.: Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission. J. Biol. Chem. 283, 23200-23208 (2008).
52. Pommier, Y.: Repair oftopoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 81, 179-229 (2006).
53. Bertrand, R., Solary, E., Kohn, K.W., O'Connor, P. and Pommier, Y.: Induction of a common pathway to apoptosis by staurosporine. Exp. Cell Res. 211, 314-321 (1994).
54. Pommier, Y. and Cherfils, J.: Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol. Sci. 28, 136-145 (2005).
55. Marchand, C.: A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes. Mol. Cancer Ther. 5, 287-295 (2006).
56. Nitiss, J. and Wang, J.C.: DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sa'. USA 85, 7501-7505 (1988).
57. Bjornsti, M.-A., Benedetti, P., Viglianti, G.A. and Wang, J.C.: Expression of human DNA topoisomerase I inYeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 49, 6318-6323 (1989).
58. Wall, M.E. and Wani, M.C.: Camptothecin and taxol: discovery to clinic—thirteenth Bruce F. Cain Memorial Award lecture. CancerRes. 55, 753-760 (1995).
59. Sirikantaramas, S., Yamazaki, M. and Saito, K.: Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc. Natl. Acad. Sci. USA 105, 6782-6786 (2008).
60. Fujimori, A., Harker, W.G., Kohlhagen, G., Hoki, Y. and Pommier, Y.: Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res. 55, 1339-1346 (1995).
61. Hsiang, Y.H., Hertzberg, R., Hecht, S. and Liu, L.F.: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260, 14873-14878 (1985).
62. Teicher, B.A.: Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 75, 1262-1271 (2008).
63. Pratesi, G., Beretta, G.L. and Zunino, F.: Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15, 545-552 (2004).
64. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E. and Pommier, Y.: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49, 1465-1469 (1989).
65. Hsiang, Y.H.: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49, 4385-4389 (1989).
66. Mi, Z. and Burke, T.G.: Differential interactions of camptothecin lactone and carboxylateformswith human blood components. Biochemistry 33,10325-10336 (1994).
67. Strumberg, D.: Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell Biol. 20, 3977-3987 (2000).
68. Lavergne, O.: Homocamptothecins: synthesis and antitumoractivity ofnovel E-ring-modified camptothecin analogues. J. Med. Chem. 41, 5410-5419 (1998).
69. Bailly, C.: Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol. 45, 91-108 (2003).
70. Hautefaye, P.: Synthesis and pharmacological evaluation of novel nonlactone analogues of camptothecin. Bioorg Med. Chem. Lett. 13, 2731-2735 (2003).
71. Meng, L.-H., Liao, Z.-Y. and Pommier, Y.: Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr. Topics Med. Chem. 3, 305-320 (2003).
72. Bailly, C.: Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. 7, 39-58 (2000).
73. Paull, K.D.: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of a mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81, 1088-1092 (1989).
74. Yamashita, Y.: Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31, 12069-12075 (1992).
75. Long, B.H., Rose, W.C., Vyas, D.M., Matson, J.A. and Forenza, S.: Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr. Med. Chem. Anticancer Agents 2, 255-266 (2002).
76. Li, T.K.: Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res. 63, 8400-8407 (2003).
77. Morrell, A., Antony, S., Kohlhagen, G., Pommier, Y. and Cushman, M.: A systematic study ofnitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J. Med. Chem. 49, 7740-7753 (2006).
78. Antony, S.: Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 63, 7428-7435 (2003).
79. Morrell, A.: Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay. Bioorg. Med. Chem. 16, 4395-4399 (2006).
80. Morrell, A.: Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J. Med. Chem. 50, 4419-4430 (2007).
81. Morrell, A.: Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J. Med. Chem. 50, 2040-2048 (2007).
82. Svejstrup, J.Q., Christiansen, K., Andersen, A.H., Lund, K. and Westergaard, O.: Minimal DNA duplex requirements fortopoisomerase I-mediated cleavage in vitro. J. Biol. Chem. 265, 12529-12535 (1990).
83. Bonven, B.J., Gocke, E. and Westergaard, O.: A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 41, 541-551 (1985).
84. Christiansen, K., Svejstrup, A.B., Andersen, A.H. and Westergaard, O.: Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination. J. Biol. Chem. 268, 9690-9701 (1993).
85. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K.W. and Pommier, Y.: Effect oflocal DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 266, 20418-20423 (1991).
86. Antony, S.: Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propyla mino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol. 70, 1109-1120 (2006).
87. Bjornsti, M.-A. and Osheroff, N.: DNA topoisomerase protocols. DNA topology and enzymes Vol. 94 (Humana Press, Totowa, NJ, 1999).
88. Pommier, Y., Covey, J.M., Kerrigan, D., Markovits, J. and Pham, R.: DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res. 15, 6713-6731 (1987).
89. Jaxel, C., Kohn, K.W. and Pommier, Y.: Topoisomerase I interaction with SV40 DNAin the presence and absence of camptothecin. Nucleic Acids Res. 16, 11157-11170 (1988).
90. McClendon, A.K. and Osheroff, N.: The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. Biochemistry 45, 3040-3050 (2006).
91. Kohn, K.W. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 18, 505-513 (1996).
92. Trask, D.K., DiDonato, J.A. and Muller, M.T.: Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. Embo. J. 3, 671-676 (1984).
93. El-Khamisy, S.F.: Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434, 108-113 (2005).
94. Laco, G.S.: Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies. Bioorg. Med. Chem. 12, 5225-5235 (2004).
95. Maxam, A. and Gilbert, W.: Sequencing end-labeled DNA with base-specific chemical cleavages. Meth. Enzymol. 65, 499-560 (1980).
96. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J. and Laco, G.S.: Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat. 2, 307-318 (1999).
97. Yoshinari, T.: Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 59, 4271-4275 (1999).
98. Zhu, S.: Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. Bioorg. Med. Chem. 13, 6782-6794 (2005).